Introduction
Focal and segmental glomerulosclerosis (FSGS) is a glomerular disease that may affect both children and adults. Clinically, FSGS is characterized by severe proteinuria and microscopic haematuria. Hypertension is frequent, and a number of patients have some degree of renal dysfunction at presentation. The prognosis of untreated patients with FSGS is poor, as the disease is usually progressive. Approximately 50±70% of adults with FSGS and an associated nephrotic syndrome either die or develop end-stage renal disease within 10 years from the clinical onset.
The two most important clinical variables associated with renal failure are severe proteinuria [1] and a high level of serum creatinine at the time of renal biopsy [2, 3] . Among histological features, the extent of interstitial ®brosis is the strongest predictor of renal outcome [1,4,5,6 . ]. A recent study [7 . ] showed that the risk of renal failure may also be associated with the presence of cellular lesion' proliferation, hypertrophy, and pathological changes in the cells overlying the glomerular scar. On the other hand, the remission of proteinuria, either spontaneous or after treatment, usually heralds a favourable renal outcome [2,8,9 . . ]. Any form of treatment able to obtain remission is thus likely to prevent not only the consequences of the nephrotic syndrome but also the development of progressive renal failure. Angiotensin-converting enzyme inhibitors may reduce proteinuria and preserve renal function in renal diseases [10] . Although there is no formal evidence that these agents can modify the outcome of FSGS, they are usually prescribed, together with statins and diuretics for the supportive therapy of nephrotic patients. Several therapeutic trials have been attempted in order to improve the outcome of FSGS.
Corticosteroids
In a review of the studies published between 1961 and 1986, Meyrier [11 . . ] found that only 15.6% of patients treated with corticosteroids had a complete remission of proteinuria, and another 20.2% had a partial remission of the nephrotic syndrome (i.e. non-nephrotic proteinuria). However, most patients were treated for a short period of time. Better chances of remission have been reported in patients receiving corticosteroids for at least 6 months [2, 4, 12] . Of interest is the fact that the responders tended to maintain normal renal function in the long term, in spite of the fact that many of them had a relapse of the nephrotic syndrome. The advantage of a prolonged administration of prednisone was recently con®rmed by an Italian retrospective study [13 . . ]. Fiftythree adult nephrotic patients with FSGS and serum creatinine levels less than 3 mg/dl were treated with corticosteroids for a mean of 24.5+25.6 weeks. The probability of surviving for 10 years without the doubling of plasma creatinine was 69%, considerably better than the 30±50% reported by others [8, 14, 15] . Of note was the fact that only 15% of patients who received corticosteroids for 16 weeks or less obtained complete remission, compared with 61% of complete remissions in patients treated for more than 16 weeks. Similar results were reported by Alexopoulos et al. [16 . . ] , who obtained remission in 64% of nephrotic patients with prednisolone given for an average of 9 months. Alternate-day administration may reduce the morbidity of prolonged steroid therapy. Comparing a 6-month course of alternate-day prednisone with a daily prednisone regimen, Matalon et al. [17 . . ] reported an equivalent incidence of remission with the two treatment schedules, but side-effects were less frequent in patients given alternate-day steroids. Some investigators could not ®nd any clinical or histological features predictive of the response [2, 4] , whereas others found that interstitial ®brosis was associated with a poor response [16 . . ] . Recently, Briggs et al. [18 . ] demonstrated that the pretreatment suppressive effect of steroids on lymphocyte proliferation was related to responses of creatinine clearance or nephrotic proteinuria.
In summary, prolonged treatment with corticosteroids can favour remission of the nephrotic syndrome and can help in preserving renal function over time. However, some patients do not tolerate these agents and a number of responders show a relapse of the nephrotic syndrome, needing further treatments that expose them to steroidrelated toxicity.
Cytotoxic agents
It is dif®cult to evaluate the ef®cacy of cytotoxic drugs in FSGS because most of the available studies are retrospective and with short-term follow-ups. Cytotoxic agents have usually been used as a second-line treatment either in patients who showed frequent relapses after an initial response to steroids or in steroid-resistant patients. An analysis of retrospective studies [11 . . ] showed that in steroid-responsive patients cytotoxic agents could obtain complete remission in 50% of cases and partial remission in another 25% of patients. The response was lower in steroid-resistant patients. Only 10% of patients given cytotoxic agents entered complete remission and another 10% achieved partial remission. When given as a ®rst-line treatment cytotoxic agents, administered in median for 75 weeks, obtained complete remission in 30% of patients and partial remission in another 11%. Relapse of the nephrotic syndrome occurred in only 27% of the responders [13 . . ].
These data suggest that cytotoxic agents are of little bene®t in inducing remission in comparison with corticosteroids but may prolong the duration of remission. Recently, intravenous pulses of cyclophosphamide, together with oral prednisone have been used. This regimen obtained complete remission in two out of ®ve steroid-resistant children and in ®ve out of ®ve children who were initially steroid dependent and later developed steroid resistance [19 . ]. These results were con®rmed in another study [20 . ] showing a complete remission of the nephrotic syndrome in 13 out of 20 children treated with this regimen.
A regimen with cyclophosphamide or chlorambucil in combination with intravenous pulses of methylprednisolone and oral corticosteroids has been reported to obtain good results in steroid-resistant children by Mendoza et al. [21] . At the last follow-up (mean 6 years), among 32 children treated with this regimen, 66% were in complete remission and another 16% were in partial remission [22] . This high rate of responsiveness was con®rmed by a recent study [23 . ] also in African-American children with FSGS and renal function impairment. The administration of the regimen of Mendoza et al.
[21] normalized renal function and reduced proteinuria in three out of ®ve nephrotic patients with a pretreatment creatinine clearance of less than 50 ml/min. 
Inhibitors of purine synthesis

Cyclosporine
Another possible option for patients with FSGS is represented by cyclosporine A. A recent review of several retrospective studies in children and adults treated with this agent [28] showed that 21% of adults and 39% of children could be maintained in complete remission under cyclosporine. The analysis of those studies indicated that the rate of response was lower in steroidresistant than in steroid-sensitive patients. The combination of cyclosporine with small doses of corticosteroids improved the rate of remission. In the majority of responders, proteinuria disappeared within 3±6 months from the beginning of treatment. Most patients had early relapses of the nephrotic syndrome after withdrawal of cyclosporine, but some patients could maintain remission if cyclosporine was tapered off very gradually.
Four randomized trials with the use of cyclosporine in FSGS have been published [29±31,32 . . ]. In a cross-over study, Walker and Kincaid-Smith [29] randomly assigned nine patients with steroid-resistant FSGS to either a 4±6 month course with cyclosporine plus warfarin or to a control period with warfarin alone. Proteinuria signi®cantly decreased and serum albumin signi®cantly increased under cyclosporine. The follow-up was too short to assess the effects of cyclosporine on renal function. Ponticelli et al.
[30] randomly assigned 45 patients with nephrotic syndrome who did not respond to treatment with 6 weeks of high-dose prednisone either to symptomatic treatment or to cyclosporine for 6 months, with gradual tapering off over the following 6 months. In the ®rst year of study, seven out of 22 patients treated with cyclosporine (32%) obtained complete remission and six (27%) obtained partial remission compared with three (16%) partial remissions in the control group. Of patients who responded to cyclosporine, 38% maintained remission of the nephrotic syndrome one year after stopping cyclosporine. Creatinine clearance decreased by more than 50% in one cyclosporine-treated patient and in four controls. In another study [31] , 25 children with corticosteroid-resistant FSGS were randomly assigned to receive either placebo or cyclosporine for 6 months. All patients assigned to cyclosporine had a reduction of proteinuria compared with only two of the 12 placebotreated patients. Cattran et al. [32 . . ] randomly assigned 49 adults with FSGS and nephrotic syndrome to cyclosporine, 3.5 mg/kg per day for 26 weeks, or to placebo. Seventy per cent of the treated patients had complete or partial remission of proteinuria compared with 4% who obtained partial remission in the placebo group (P50.001). Relapse occurred in 40% of responders by 52 weeks and in 60% by week 78, the other patients remained in remission. There was a decrease of 50% in baseline creatinine clearance in 25% of the treated group compared with 52% of controls, the difference being signi®cant.
In summary, cyclosporine may obtain remission of the nephrotic syndrome in approximately 40±60% of patients and may therefore be considered as an alternative to corticosteroids or immunosuppressive agents. There is some concern, however, with the use of cyclosporine in FSGS, as its nephrotoxicity may accelerate the progression of renal disease. Miller et al.
[33] found that serum creatinine levels did not change when cyclosporine was stopped in those patients who started treatment with normal renal function and responded to cyclosporine. However, Habib and Niaudet [34] and Melocoton et al. [35] warned that histological lesions may develop even in patients who maintain normal serum creatinine levels. Meyrier et al.
[36], in a study with repeat renal biopsies, found that three factors were associated with the risk of cyclosporine nephropathy: an abnormal baseline serum creatinine level, a high percentage of sclerotic glomeruli at initial biopsy and an initial dosage of cyclosporine greater than 5.5 mg/kg per day. It should thus be recommended to limit the use of cyclosporine to patients with normal renal function, without diffuse glomerular sclerosis or interstitial ®brosis at biopsy and at doses lower than 5 mg/kg per day. Monitoring of serum creatinine levels and of blood pressure, and appropriate adjustment of the doses may further reduce the risk of nephrotoxicity [28] .
Tacrolimus
This calcineurin inhibitor has also been used in FSGS. A recent paper [37] reported the effects of tacrolimus in four children with FSGS who had failed to respond to steroids and cytotoxic agents or to cyclosporine. Complete remission was seen in two patients, and a signi®cant reduction of proteinuria was observed in two other children. However, tacrolimus induced a rapid increase in serum creatinine levels, and attempts to stop the drug were followed by relapses of the nephrotic syndrome.
Vitamin E
In murine models of FSGS, scavengers of oxygen radicals and lipid peroxidation can interfere with the development of FSGS [38 . . ,39 . . ]. Tahzib et al. [40 . ] recently investigated whether vitamin E supplementation could also reduce proteinuria in children with FSGS. In 11 children, treatment with vitamin E, 200 IU twice a day for a mean period of 2.9 months, reduced the urine protein : creatinine ratio in 10 cases, from 9.7+5.1 to 4.1+1.1 (P50.005).
Pefloxacin
The rationale for the use of this drug is based on its immunomodulatory role [41, 42] . Few studies investigating the role of pe¯oxacin in idiopathic nephrotic syndrome reported con¯icting results [43, 44] . However, such studies included a small number of patients, belonging to different age groups, with variable steroid responsiveness and treated with different doses of pe¯oxacin. More recently, Sharma et al. [45 . ] treated seven children with steroid-resistant or -dependent FSGS with pe¯oxacin, 200±400 mg twice a day, for 4± 8 weeks. Among treated patients, two had complete remission and three a partial remission of the nephrotic syndrome. The ®rst response to pe¯oxacin, as well as the response of relapses of the nephrotic syndrome, was correlated to the steroid response. The authors suggested that pe¯oxacin could be considered as a therapeutic alternative in children with FSGS.
Apheresis-immunoadsorption
The use of plasmapheresis or immunoadsorption may theoretically be helpful for removing a plasma factor that may be responsible for glomerular damage and proteinuria [46,47 . . ,48] . Good results have been reported in patients with nephrotic syndrome of various aetiologies [49 . ] and in patients with a recurrence of FSGS after transplantation [50 . ]. In some patients with FSGS on native kidneys, plasmapheresis may reduce proteinuria and stabilize renal function [51, 52] . Protein A immunoadsorption has been used in ®ve patients with FSGS. Proteinuria was reduced from 9 to 0.5 g/day in one case treated for 18 months, and from 9 to 4 g/day in another patient [53] . Finally, a signi®cant reduction of protein-uria was seen with LDL-apheresis in 17 patients with FSGS, with a rate of complete or incomplete remission of 71% [54 . . ].
Conclusion
There is currently an emerging consensus that prolonged steroid therapy should be offered to patients with FSGS and the nephrotic syndrome. The recent Canadian guidelines recommended the administration of prednisone for at least 6 months as a ®rst approach [55 . . ]. In steroid-resistant patients or in those with contraindications, a course with an alkylating agent may be tried, although only a few adults respond. Better results can be obtained in children by combining high-dose methylprednisolone pulses, alternate-day prednisone and an alkylating agent. A third therapeutic possibility is cyclosporine. This agent is particularly appropriate in the presence of contraindications to corticosteroids, as well as in corticodependency. Cyclosporine is less ef®cacious in corticoresistant patients, although some patients may achieve an improvement of proteinuria under cyclosporine. Therefore, a trial of cyclosporine may also be justi®ed in those patients. The role of azathioprine, MMF, tacrolimus, pe¯oxacin or vitamin E in the treatment of FSGS is still poorly de®ned. Plasmapheresis or LDL-apheresis may be tried as a rescue treatment in selected patients who do not respond to other therapies.
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Papers of particular interest, published within the annual period of review, have been highlighted as: 1348±1356. This study confirms that nephrotic patients may benefit from a course of prednisone for at least 6 months, and responders have a better renal survival rate than non-responders. The severity of tubulointerstitial fibrosis is predictive of response to treatment, whereas age and plasma creatinine are independent risk factors for end-stage renal disease. 
